ANAKINRA EFFICACY IN COVID-19 PNEUMONIA GUIDED BY SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR: ASSOCIATION WITH THE INFLAMMATORY BURDEN OF THE HOST.
Coronavirus Literature
Publication date: Dec 06, 2024 Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the Food and Drug Administration of the United States for patients ... Read more